Heitmann, J. S., Schlenk, R. F., Dörfel, D., Kayser, S., Döhner, K., Heuser, M., . . . Salih, H. R. (2023). Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease. Journal of hematology & oncology, 16, . https://doi.org/10.1186/s13045-023-01490-w
Chicago-Zitierstil (17. Ausg.)Heitmann, Jonas S., et al. "Phase I Study Evaluating the Fc-optimized FLT3 Antibody FLYSYN in AML Patients with Measurable Residual Disease." Journal of Hematology & Oncology 16 (2023). https://doi.org/10.1186/s13045-023-01490-w.
MLA-Zitierstil (9. Ausg.)Heitmann, Jonas S., et al. "Phase I Study Evaluating the Fc-optimized FLT3 Antibody FLYSYN in AML Patients with Measurable Residual Disease." Journal of Hematology & Oncology, vol. 16, 2023, https://doi.org/10.1186/s13045-023-01490-w.